Abstract:A receptor-based pharmacophore model describing the binding features required for the multi-kinase inhibition of the target kinases (VEGFR-2, FGFR-1, and BRAF) were constructed and validated. It showed a good overall quality in discriminating between the active and the inactive in a compiled test set compounds with F1 score of 0.502 and Mathew's correlation coefficient of 0.513. It described the ligand binding to the hinge region Cys or Ala, the glutamate residue of the Glu-Lys αC helix conserved pair, the DFG motif Asp at the activation loop, and the allosteric back pocket next to the ATP binding site. Moreover, excluded volumes were used to define the steric extent of the binding sites. The application of the developed pharmacophore model in virtual screening of an in-house scaffold dataset resulted in the identification of a benzimidazole-based scaffold as a promising hit within the dataset. Compounds 8a-u were designed through structural optimization of the hit benzimidazole-based scaffold through (un)substituted aryl substitution on 2 and 5 positions of the benzimidazole ring. Molecular docking simulations and ADME properties predictions confirmed the promising characteristics of the designed compounds in terms of binding affinity and pharmacokinetic properties, respectively. The designed compounds 8a-u were synthesized, and they demonstrated moderate to potent VEGFR-2 inhibitory activity at 10 μM. Compound 8u exhibited a potent inhibitory activity against the target kinases (VEGFR-2, FGFR-1, and BRAF) with IC 50 values of 0.93, 3.74, 0.25 μM, respectively. The benzimidazole derivatives 8a-u were all selected by the NCI (USA) to conduct their anti-proliferation screening. Compounds 8a and 8d resulted in a potent mean growth inhibition % (GI%) of 97.73% and 92.51%, respectively. Whereas compounds 8h , 8j , 8k , 8o , 8q , 8r , and 8u showed a mean GI% > 100% (lethal effect). The most potent compounds on the NCI panel of 60 different cancer cell lines were progressed further to NCI five-dose testing. The benzimidazole derivatives 8a , 8d , 8h , 8j , 8k , 8o , 8q , 8r and 8u exhibited potent anticancer activity on the tested cell lines reaching sub-micromolar range. Moreover, 8u was found to induce cell cycle arrest of MCF-7 cell line at the G2/M phase and accumulating cells at the sub-G1 phase as a result of cell apoptosis.

Synthesis, Biological Evaluation and Molecular Docking Studies of Flavone and Isoflavone Derivatives As a Novel Class of KSP (kinesin Spindle Protein) Inhibitors

Design, Synthesis, And Interaction Study Of Quinazoline-2(1h)-Thione Derivatives As Novel Potential Bcl-X(L) Inhibitors

New Application of Novel Tetrazine Derivatives As Potent VEGFR-2 Kinase Inhibitors and Anti-Cancer Agents

Discovery of Novel KSP-targeting PROTACs with Potent Antitumor Effects in Vitro and in Vivo

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

Synthesis, Biological Evaluation and Molecular Docking Studies of Pyrazole Derivatives Coupling with a Thiourea Moiety As Novel CDKs Inhibitors.

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors

Identifying and characterising promising small molecule inhibitors of kinesin spindle protein using ligand-based virtual screening, molecular docking, molecular dynamics and MM‐GBSA calculations

Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel 1,3,4-Oxadiazole Derivatives Possessing Benzotriazole Moiety As FAK Inhibitors with Anticancer Activity.

Synthesis and biological evaluation of 2-aryl-benzimidazole derivatives of dehydroabietic acid as novel tubulin polymerization inhibitors

Identification, characterization and biological studies of Kinesine spindle protein inhibitor, benzo[b] [1, 4]oxazine-6-carboxamide derivative, via 3D-pharmacophore virtual screening

Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives As Novel Inhibitors of VEGFR2.

Synthesis and biological evaluation of novel indole derivatives containing sulfonamide scaffold as potential tubulin inhibitor

Design, synthesis and biological evaluation of vinyl selenone derivatives as novel microtubule polymerization inhibitors

Design and Synthesis of Indole Pyrimidine Scaffolds as Potential KSP Inhibitors and Anticancer Agents

Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6

Design, Synthesis and Biological Evaluation of 9-Aryl-5h-pyrido[4,3-b]indole Derivatives As Potential Tubulin Polymerization Inhibitors.

Synthesis, Biological Evaluation and Molecular Docking Studies of Novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone Derivatives

Novel 2-Sulfanylquinazolin-4(3H)-one Derivatives as Multi-Kinase Inhibitors and Apoptosis Inducers: A Synthesis, Biological Evaluation, and Molecular Docking Study

Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure